A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Formulation and Determination of Intravenous Pharmacokinetics
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2018
At a glance
- Drugs MEDI-7219 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 22 Aug 2018 Planned End Date changed from 19 Oct 2018 to 29 Mar 2019.
- 02 Aug 2018 Planned primary completion date changed from 19 Oct 2018 to 29 Mar 2019.
- 23 Jul 2018 Planned number of patients changed from 126 to 104.